Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

To be considered for this study, you would need to be at least 18 years old and have pancreatic cancer that has spread to other parts of your body. An important requirement is that your cancer must show a high number of specific genetic changes, or a particular type of genetic fault, which will be checked by doctors.

You should generally be in good health, with important organs like your bones, liver, and kidneys working well within acceptable limits. You should also not have received too much prior treatment – usually no more than one previous chemotherapy or other similar treatment for your advanced cancer. Additionally, you cannot have had certain types of immunotherapy or PARP inhibitor drugs before.

The medical team will carefully review all your health information and test results to make sure this study is the right fit for you and that it's safe for you to take part. This ensures the study is conducted responsibly and focuses on gathering valuable information for patients who might benefit most.

If you join this study, you will receive both pembrolizumab and olaparib. Pembrolizumab is given as a drip into a vein, while olaparib is taken as tablets. The exact schedule for these medications will be explained by the study team. You will have regular visits to the clinic for medical check-ups, blood tests, and scans to monitor your health and how the treatment is working. These assessments are important to track the cancer, manage any side effects, and ensure your safety.

The study is ongoing, meaning there isn't a fixed total duration for every patient. Treatment will continue as long as it is benefiting you and you are tolerating it well, unless you or your doctor decide to stop. There will also be follow-up appointments after treatment ends to see how you are doing in the longer term.